Lyme disease is caused by a specific group of Borrelia burgdorferi bacteria, which can be transmitted to humans through a bite from an infected tick. This can result in a number of clinical problems ranging from skin rash to serious involvement of organ systems, including arthritis, and neurological problems. People with skin and non-specific symptoms most commonly present to their general practitioner and are often treated in primary care, whereas people with symptoms affecting organ systems are commonly referred to specialists.
The guideline focuses on diagnosis and management of Lyme disease according to clinical presentation and symptoms rather than using the differing classifications of Lyme disease, which are poorly defined and contested. There is a lack of good quality evidence on the epidemiology, prevalence, diagnosis, and management of Lyme disease.
This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE). 
What's new in this guidance
• Tests used to support diagnosis should be carried out at UK accreditation service (UKAS) accredited laboratories that use validated tests and participate in a formal external quality assurance programme
• Doses and durations of antibiotics at the higher ranges of formulary doses and lengths of treatment are recommended
• Consider a second course of antibiotics for people with ongoing symptoms if treatment may have failed
Recommendations
NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Committee's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.
Awareness
The incidence of Lyme disease is unknown. Most estimates are based on laboratory confirmed cases and therefore do not include those diagnosed on clinical presentation alone or those that go undiagnosed. The indicative rash, erythema migrans, is not always present, noticed, or recognised, and other symptoms overlap with many other common conditions. The following recommendations were developed to raise awareness of factors affecting Lyme disease risk and when to suspect Lyme disease.
• Be aware that: -The bacteria that cause Lyme disease are transmitted by the bite of an infected tick -Ticks are mainly found in grassy and wooded areas, including urban gardens and parks -Tick bites may not always be noticed Figure 1 details the guidance for use of tests in diagnosis of Lyme disease.
• Diagnose Lyme disease in people with erythema migrans (fig 2) , a red rash that: -Increases in size and may sometimes have a central clearing -Is not usually itchy, hot, or painful -Usually becomes visible from one to four weeks (but can appear from 3 days to 3 months) after a tick bite and lasts for several weeks -Is usually at the site of a tick bite.
• Be aware that a rash that is not erythema migrans can develop as a reaction to a tick bite. This rash: -Usually develops and recedes within 48 hours from the time of the tick bite -Is more likely than erythema migrans to be hot, itchy or painful -May be caused by an inflammatory reaction or infection with a common skin pathogen.
[Based on the experience and opinion of the GC]
• Consider the possibility of Lyme disease in people presenting with several of the following symptoms, because Lyme disease is a possible but uncommon cause of: 
• Consider the possibility of Lyme disease in people presenting with symptoms and signs relating to one or more organ systems (focal symptoms) because Lyme disease is a possible but uncommon cause of: -Neurological symptoms (such as facial palsy or other unexplained cranial nerve palsies, meningitis, mononeuritis multiplex or other unexplained radiculopathy, or, rarely, encephalitis, neuropsychiatric presentations, or unexplained white matter changes on brain imaging) -Inflammatory arthritis affecting one or more joints that may be fluctuating and migratory -Cardiac problems such as heart block or pericarditis -Eye symptoms such as uveitis or keratitis -Skin rashes such as acrodermatitis chronica atrophicans or lymphocytoma.
[Based on very low quality evidence from observational studies and the experience and opinion of the GC]
• If a person presents with symptoms that suggest the possibility of Lyme disease, explore how long the person has had symptoms and their history of possible tick exposure.
-For example, ask about: ♦Activities that might have exposed them to ticks ♦Travel to areas where Lyme disease is known to be highly prevalent.
-Do not rule out the possibility of Lyme disease in people with symptoms but no clear history of tick exposure.
[Based on the experience and opinion of the GC]
• Use a combination of clinical presentation and laboratory testing to guide diagnosis and treatment in people without erythema migrans (see fig 1) . The most common laboratory tests used when Lyme disease is suspected are serological tests that detect antibodies to the bacteria causing Lyme disease. This is based on a two tier approach, where a sensitive initial test is performed first, followed by a more specific confirmatory test in case of a positive or equivocal initial test result. When combined with clinical assessment, the tests can be helpful in supporting diagnosis.
• Carry out tests for Lyme disease only at UK accreditation service (UKAS) accredited laboratories that: -Use validated tests (validation should include published evidence on the test methodology, its relation to Lyme disease, and independent reports of performance)
-Participate in a formal external quality assurance programme.
Management
The recommendations on antibiotic management aim to provide clear guidance on choice of antibiotic, dose, treatment duration, and circumstances when additional courses of treatment or referral to specialists might be considered. Doses and duration of antibiotic treatment have been chosen at the higher ranges of formulary doses and lengths of treatment to avoid the possibility of under-treatment. There was a lack of evidence to support extended courses of antibiotics for people with persisting symptoms.
• Treat people with Lyme disease according to the infographic (also supplementary tables 1 and 2 on bmj.com)
• Discuss diagnosis and management of all children and young people with Lyme disease and symptoms in addition to erythema migrans with a specialist
• If an adult with Lyme disease has focal symptoms, consider a discussion with or referral to an appropriate specialist without delaying treatment 
Explain the diagnosis and uncertainties
The uncertainty that exists as a result of lack of good evidence is difficult for people with Lyme disease and can lead to fear and frustration. It is essential that people with diagnosed or suspected Lyme disease are provided with support as well as direction to good sources of information and clear communication about diagnosis and management, including uncertainties.
• Tell people that tests for Lyme disease have limitations.
Explain that both false positive and false negative results can occur and what this means. [Based on very low quality evidence from observational studies and the experience and opinion of the GC]
• Explain that most tests for Lyme disease assess the presence of antibodies and that the accuracy of tests may be reduced if: -Testing is carried out too early (before antibodies have developed)
-The person has reduced immunity (such as a person receiving immunosuppressant treatment) which might affect the development of antibodies.
[Based on the experience and opinion of the GC]
• Explain to people with ongoing symptoms after antibiotic treatment for Lyme disease that: -Continuing symptoms may not mean they still have an active infection -Symptoms of Lyme disease may take months or years to resolve even after treatment -Some symptoms may be a consequence of permanent damage from infection -There is no test for active infection and an alternative diagnosis may explain their symptoms.

Implementation
NICE has produced tools and resources to facilitate the implementation of this guideline, including an algorithm for laboratory investigations and diagnosis of Lyme disease.
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Guidelines into practice
• Which groups of patients do you tend to test or treat for Lyme's disease? Does this guideline provide ideas on how to alter your practice?
• Which groups of patients would you discuss with a specialist for suspected Lyme's disease? Does this guideline provide ideas on how to alter your practice?
• How might you share learning from this guideline with colleagues?
Further information on the guidance
Methods
This guidance was developed by the National Guideline Centre in accordance with NICE guideline development methods (www.nice.org.uk/media/default/ about/what-we-do/our-programmes/developing-nice-guidelines-the-manual. pdf).
The Guideline Committee (GC) established by the National Guideline Centre comprised one professor of paediatric immunology and infectious diseases, two paediatric consultants in infectious diseases, one consultant in infectious diseases, one general physician, one microbiologist, one paediatric neurologist, one rheumatologist, two general practitioners, and four lay members. The GC also co-opted an adult neurologist and a pharmacist.
Review questions were developed based on key clinical areas of the scope. Systematic literature searches, critical appraisals, evidence reviews, and evaluations of cost effectiveness, where appropriate, were completed for all questions except for awareness of Lyme disease. The recommendations for raising awareness were based on discussions, consensus, and expert opinion of the GC and were also informed by other review questions. A qualitative review was undertaken to explore aspects related to the information needs of people with suspected, confirmed, or treated Lyme disease.
Quality ratings of the evidence were based on GRADE methodology (www. gradeworkinggroup.org/). These relate to the quality of the available evidence for assessed outcomes or themes rather than the quality of the study.
The scope and the draft of the guideline went through a rigorous reviewing process, in which stakeholder organisations were invited to comment; the GC took all comments into consideration when producing the final version of the guideline.
A formal review of the need to update a guideline is usually undertaken by NICE after its publication. NICE will conduct a review to determine whether the evidence base has progressed significantly to alter the guideline recommendations and warrants an update.
Other details
Different versions of this guideline have been produced: a short version containing a list of all the recommendations and a summary of why they were developed, known as the "short guideline," and individual evidence reports containing all the evidence, the process undertaken to develop the recommendations, and all the recommendations. These are available from the NICE website (www.nice.org.uk/guidance/NG95).
Future research
The GC prioritised the following research recommendations:
• Can a core outcome set be developed for clinical trials of management of Lyme disease?
• What are the incidence, presenting features, management and outcome of Lyme disease in the UK?
• What is the current seroprevalence of Lyme disease-specific antibodies and other tick-borne infections in people in the UK?
• What are the most clinically and cost effective treatment options for different clinical presentations of Lyme disease in the UK?
• What is the most clinically and cost effective serological antibody-based test, biomarker, or other test for diagnosing Lyme disease in the UK at all stages, including reinfection?
How patients were involved in the creation of this article
Committee members involved in this guideline update included four lay members who contributed to the formulation of the recommendations summarised here. 
